Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of
Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder
Compared with Advair Diskus® 100/50 in Subjects with Asthma
Phase:
N/A
Details
Lead Sponsor:
Roxane Laboratories
Collaborator:
Vectura Limited
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Salmeterol Xinafoate